Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can DNA predict transplant trouble in kids?

NCT ID NCT07194057

Knowledge-focused Sponsor: Instituto de Investigación Hospital Universitario La Paz Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study will analyze the DNA and chemical marks on DNA of 200 children who have had a liver or kidney transplant. Researchers want to find genetic clues that might explain why some children develop serious complications like organ rejection, infections, or cancer after transplant. No extra procedures are needed—samples are taken during routine care. The goal is to better predict and manage these risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Whole genome sequencing and methylation analysis
What this could lead to
If successful, this could help doctors predict and prevent complications after a child's organ transplant, improving long-term outcomes.
What could go wrong
This is an observational study, not a treatment trial. It is small (200 children) and early, so findings may not apply to all transplant patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2025

An estimate. Start dates often move.

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll paediatric patients that have underdone a renal i liver transplant

Ages

6 months to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ● Paediatric patients (6 months to 18 years old) with liver or kidney transplant. Both patients with de novo transplantation or in follow-up can be included in the study. * For the retrospective cohort, only patients within the first 5 years after transplantation will be included. * Patients and/or parents agreeing to participate in the study and provide consent for the obtention of clinical data and samples for genomic and methylomic analysis and the use of the information according to the protocol. Exclusion Criteria: * Patients that are not being followed up in the clinical site. * Subjects alternating between different clinical sites. Subjects/Tutors that don't understand the informed consent form. * Subject or their legally authorized representative does not sign the informed consent document. * Re-transplantation or AB0-incompatible transplantation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney transplant are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease related to transplantation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant Liver transplant Transplant complication

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Universitario La Paz

    Madrid, Madrid, 28046, Spain

  • Mediterranean Institute for Transplantation (ISMETT)

    Palermo, Sicily, 90127, Italy

  • University Hospital Padova

    Padova, 35128, Italy

  • University Medical Center Hamburg-Eppendorf (UKE),

    Hamburg, 20251, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.